Interpretation 165
Tier 1|
|
|
Primary Sites
Tumor Types
Interpretation
RAS mutations (HRAS, NRAS and KRAS) are found in all epithelial thyroid malignancies. The frequency of HRAS mutations in thyroid carcinomas is 4%. RAS mutations are identified in 10-20% of papillary carcinomas, 40-50% of follicular carcinomas and 20-40% of poorly differentiated and anaplastic carcinomas .
Citations
- Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71
- JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517
- De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62
- Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77
- Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47
Last updated: 2020-07-24 14:53:44 UTC